Docetaxel for the post-surgery treatment of patients with node-positive breast cancer

References

• BisseryMCNohynekGSanderinkGJDocetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experienceAnticancer Drugs199563395536387670132
   PubMed Web of Science ®Google Scholar
• BridgewaterTaxotere prescribing information2004NJAventis Pharmaceuticals Inc.
   Google Scholar
• CortesJEPazdurRDocetaxelJ Clin Oncol1995132643557595719
   PubMed Web of Science ®Google Scholar
• CrownJPFrancisPDi LeoADocetaxel (T) given concurrently with or sequentially to anthracycline-based (A) adjuvant therapy (adjRx) for patients (pts) with node-positive (N+)breast cancer (BrCa), in comparison with non-T adjRx: First results of the BIG 2–98 Trial at 5 years median follow-up (MFU)J Clin Oncol20062418S Abstract 519
   Google Scholar
• DiazJFAndreuJMAssembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competitionBiochemistry1993322747558096151
   PubMed Web of Science ®Google Scholar
• EiermannWPienkowskiTCrownJPhase lll randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide versus doxorubicin and cyclophosphamide followed by docetaxel in Her-2/neu negative early breast cancer patients with positive axillary lymph nodesProc SABCS2005 Abstract 1069
   Google Scholar
• EisenhauerEAVermorkenJBThe taxoids. Comparative clinical pharmacology and therapeutic potentialDrugs1998555309463787
   PubMed Web of Science ®Google Scholar
• EsmaeliBValeroVAhmadiMACanalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effectOphthalmology2001108994511320034
   PubMed Web of Science ®Google Scholar
• EsmaeliBManagement of excessive tearing as a side effect of docetaxelClin Breast Cancer20055455715748466
   PubMedGoogle Scholar
• HainsworthJDBurrisHA3GrecoFAWeekly administration of docetaxel (Taxotere): summary of clinical dataSemin Oncol199926Suppl 10192410437747
   PubMed Web of Science ®Google Scholar
• HendersonICBerryDADemetriGDImproved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancerJ Clin Oncol2003219768312637460
   PubMed Web of Science ®Google Scholar
• JonesSESavinMAHolmesFAPhase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancerJ Clin Oncol2006245381717135639
   PubMed Web of Science ®Google Scholar
• MarkmanMManaging taxane toxicitiesSupport Care Cancer200311144712618923
   PubMed Web of Science ®Google Scholar
• MartinMPienkowskiTMackeyJAdjuvant docetaxel for node-positive breast cancerN Engl J Med200535223021315930421
   PubMed Web of Science ®Google Scholar
• MichaudLBValeroVHortobagyiGRisks and benefits of taxanes in breast and ovarian cancerDrug Safety2000234012811085347
   PubMed Web of Science ®Google Scholar
• PiccartMJKlijnJParidaensRCorticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast CancerJ Clin Oncol1997153149559294478
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJProcterMLeyland-JonesBTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med200535316597216236737
   PubMed Web of Science ®Google Scholar
• PiedboisP-PSerinDPriouFAERO-B03: A randomized phase ll trial of dose-dense, docetaxel in node-positive breast cancerJ Clin Oncol20052316S Abstract 647
   Google Scholar
• RavdinPMBurrisHA3CookGPhase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancerJ Clin Oncol1995132879858523050
   PubMed Web of Science ®Google Scholar
• RingelIHorwitzSBStudies with RP 56976 (taxotere): a semisynthetic analogue of taxolJ Natl Cancer Inst199183288911671606
   PubMed Web of Science ®Google Scholar
• RochéHFumoleauPSpielmannMSequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 TrialJ Clin Oncol20062456647117116941
   PubMed Web of Science ®Google Scholar
• RomondEHPerezEABryantJTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med200535316738416236738
   PubMed Web of Science ®Google Scholar
• SchrijversDWandersJDirixLCoping with toxicities of docetaxel (Taxotere)Ann Oncol19934610118103352
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNPhase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC⇒T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC⇒TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 studyProc SABCS2005 Abstract 1
   Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013447839211248153
   PubMed Web of Science ®Google Scholar
• SpielmannMRochéHDelozierTSafety analysis from PACS 04-A phase lll trial comparing 6 cycles of FEC 100 with 6 cycles of ET75 for node-positive early breast cancer patients followed by sequential trastuzumab in HER2 patients: Preliminary resultsJ Clin Oncol20062418S Abstract 632
   PubMedGoogle Scholar
• TrudeauMCharbonneauFGelmonKSelection of adjuvant chemotherapy for treatment of node-positive breast cancerLancet Oncol200568869816257797
   PubMed Web of Science ®Google Scholar
• ValeriaFEsterEModesto D’AprileA feasibilty study of a sequential dose-dense adjuvant regimen with epidoxorubicin followed by docetaxel followed by high-dose cyclophosphamide for early breast cancer with 4 or more lymph node metastasesAnnals of Oncol2001124S52
   Google Scholar
• ValeroVHolmesFAWaltersRSPhase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancerJ Clin Oncol1995132886948523051
   PubMed Web of Science ®Google Scholar
• ValeroVJonesSEVon HoffDDA phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancerJ Clin Oncol199816336289779713
   PubMed Web of Science ®Google Scholar
• VerschraegenCFSittisomwongTKudelkaAPDocetaxel for patients with paclitaxel-resistant Mullerian carcinomaJ Clin Oncol2000182733910894873
   PubMed Web of Science ®Google Scholar
• VogelCLMackeyJRMartinMThe role of growth factor support following neutropenic events n early stage breast cancer (BC) patients treated with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC): A sub-analysis of BCIRG 001J Clin Oncol20042214S Abstract 677
   PubMedGoogle Scholar
• ZimmermanGCKeelingJHBurrisHAAcute cutaneous reactions to docetaxel, a new chemotherapeutic agentArch Dermatol199513120267857119
   PubMed Web of Science ®Google Scholar
• ZimmermanGCKeelingJHLowryMPrevention of docetaxel-induced erythrodysesthesia with local hypothermiaJ Natl Cancer Inst19948655787907667
   PubMedGoogle Scholar